Dr. Michelle S. Bradbury

Michelle S. Bradbury, M.D., Ph.D. is a board-certified diagnostic radiologist with special expertise in the imaging of the nervous system (neuroradiology) at the Nano Center at Memorial Sloan-Kettering. She specializes in anatomic and functional CT and MRI of the brain, neck, and spine.
 
As a physician-scientist, she also pursues laboratory research in an effort to refine imaging methods and develop new approaches that can be taken to the clinic and used to gather more information about tumors, and also to deliver novel therapies. Specifically, as a member of the Nano Center, she is collaborating with other investigators at Memorial Sloan-Kettering and the Department of Material Sciences and Engineering at Cornell University in Ithaca to design and develop very tiny substances called nanoparticles that can be used to detect and treat tumors and associated metastatic disease (cancer spread).
 
Because these particles attach to specific cells, they could serve as tracers, tagged with both a fluorescent dye and radiolabeled and visualized with optical and PET imaging to detect tumor cells and metastases in the body more effectively than the tracers we use today. They may even potentially be used by surgeons right in the operating room to assess the extent of tumor spread.
 
Sentinel lymph node mapping (a staging procedure using these tracers to see if the first node to which cancer cells would spread actually contains cancer cells) is one such study that is under way in animal models, in collaboration with the Head and Neck Service in the Department of Surgery. In addition, she is in the process of attaching therapeutic drugs to these nanoparticles, so they may also have a place in cancer therapy. These studies began in the laboratory and are moving into clinical trials in collaboration with the Department of Surgery.
 
With her colleagues in the Brain Tumor Center, Michelle is studying the use of a piece of a protein called a peptide which is attached to a chemotherapy drug for the treatment of brain tumors. This complex could possibly be more successful in passing through the blood-brain barrier and get to tumor cells more effectively than conventional drugs. She is also evaluating new ways to combine MRI findings with data from PET scanning to gain more knowledge about the molecular biology of brain tumors.
 
Michelle coauthored Mesenteric Venous Thrombosis: Diagnosis and Noninvasive Imaging, Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3’-Deoxy-3’-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas, Noninvasive Assessment of Portomesenteric Venous Thrombosis: Current Concepts and Imaging Strategies, Method for Combined FDG-PET and Radiographic Imaging of Primary Breast Cancers, and Optical bioluminescence imaging of human ES cell progeny in the rodent CNS.
 
In all of her research, her goal is to develop novel approaches that increase our ability to target tumor cells to improve the diagnosis, staging, and treatment of cancers, and to ultimately improve survival and prognosis for patients.
 
Michelle earned her M.D. at George Washington University School of Medicine and her Ph.D. at the Massachusetts Institute of Technology (MIT).
 
Read Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial.